UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2022

Commission File Number: 001-39173

I-MAB

Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District
Shanghai, 201210
People's Republic of China
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

I-MAB

By: /s/ John Long
Name: John Long
Title: Director and Chief Financial Officer

Date: January 28, 2022

Exhibit Index

Exhibit 99.1—Press Release

Exhibit 99.1

I-Mab's Announcement on Unusual Price Movement

SHANGHAI, China, and GAITHERSBURG, MD. – I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics. The Company has noted the recent unusual fluctuations in the price and trading volume of the American depositary shares (the "**ADSs**") of the Company and emphasizes that its business and pipeline developments are all well on track and have no adverse changes. The Company has strong confidence in its global competitive pipeline and is accelerating ongoing transformation towards an integrated global biopharma as planned.

Latest Development of Lemzoparlimab and Uliledlimab:

- Lemzoparlimab: multiple clinical studies are ongoing in both the U.S. and China, including lemzoparlimab in combination with azacytidine in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML), in combination with rituximab in non-Hodgekin's lymphoma (NHL), and in combination with pembrolizumab (Keytruda ®) or toripalimab (TUOYI ®) in advanced solid tumors. Based on data from multiple on-going clinical trials so far, approximately 180 patients, including 120 patients with hemetological maglinancies, have been treated with lemzoparlimab without the need for priming dosing, and showed anti-tumor activity and a favorable safety profile and lack of a unwanted "sink effect". Data readout from MDS, NHL and solid tumor clinical trials is expected in 2022.
- Uliledlimab in combination with toripalimab (TUOYI®) : The China phase 2 cohort expansion study in patients with advanced or metastatic cancers who are refractory to or intolerant of all available therapies is ongoing. The company expects to submit the preliminary data to ASCO 2022.
- In 2022, the Company expects to deliver a series of significant clinical milestones. As a result, the pipeline will be advanced to include 3—4 registrational clinical trials (lemzoparlimab, estansomatropin, felzartamab), 11 Phase 2 clinical trials (including 8 new trials) and 3 Phase 1 clinical trials by end of 2022.

Financial Position:

- The company has strong cash position with approximately $700 million, as of 31 December, 2021.

Shanghai (HQ)
Suites 802, 505, 702, West Tower
88 Shangke Road, Pudong New District Shanghai,
China

United States
Suite 710, 9801 Washingtonian Blvd
Gaithersburg
Maryland 20878

www.i-mabbiopharma.com

- Between 2022 to 2023, the company expects to receive over $100 million cash from the existing out-licensing deals. The current cash on hand is sufficient to fund the Company's operations for three years.

The Company's fundamentals remain very strong. In 2021, I-Mab has successfully delivered planned important clinical and corporate milestones and will continue building on the strong momentum to deliver critical new milestones, including reporting multiple key clinical data readouts, initiating new registrational trials and accelerating dual listing on The Main Board of The Stock Exchange of Hong Kong Limited, continually creating value for patients and shareholders.

###

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

I-Mab Forward Looking Statements

This press release includes certain disclosures which contain "forward-looking statements." You can identify forward-looking statements because they contain words such as "anticipate" and "expected." Forward-looking statements are based on I-Mab's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Shanghai (HQ)
Suites 802, 505, 702, West Tower
88 Shangke Road, Pudong New District Shanghai,
China

United States
Suite 710, 9801 Washingtonian Blvd
Gaithersburg
Maryland 20878

www.i-mabbiopharma.com

I-Mab Contacts

John Long
Chief Financial Officer
john.long@i-mabbiopharma.com
+86 21 6057 8000

Gigi Feng
Chief Communications Officer
gigi.feng@i-mabbiopharma.com
+86 21 6057 8000

Investor Inquiries

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363

Shanghai (HQ)
Suites 802, 505, 702, West Tower
88 Shangke Road, Pudong New District Shanghai,
China

United States
Suite 710, 9801 Washingtonian Blvd
Gaithersburg
Maryland 20878

www.i-mabbiopharma.com